Phosphorylation of vasodilator-stimulated phosphoprotein prevents platelet-neutrophil complex formation and dampens myocardial ischemia-reperfusion injury

Circulation

Volumn 123, Issue 22, 2011, Pages 2579-2590

  Köhler, David ^a   Straub, Andreas ^a   Weissmüller, Thomas ^d   Faigle, Marion ^a   Bender, Sarah ^a   Lehmann, Rainer ^b   Wendel, Hans Peter ^c   Kurz, Julia ^c   Walter, Ulrich ^e   Zacharowski, Kai ^f   Rosenberger, Peter ^a,f,g  

^a Department of Anesthesiology and Intensive Care Medicine ^*  (Germany)

^b Division of Clinical Chemistry   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g GOETHE UNIVERSITY   (Germany)

Author keywords

ischemia reperfusion injury; myocardial infarction; phosphorylation; vasodilator stimulated phosphoprotein

Indexed keywords

VASODILATOR STIMULATED PHOSPHOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NEUTROPHIL; NONHUMAN; PLATELET NEUTROPHIL COMPLEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY; THROMBOCYTE; THROMBOCYTE FUNCTION; TISSUE INJURY;

ANIMALS; BLOOD PLATELETS; CELL ADHESION MOLECULES; CELL MOVEMENT; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROFILAMENT PROTEINS; MYOCARDIAL REPERFUSION INJURY; NEUTROPHILS; PHOSPHOPROTEINS; PHOSPHORYLATION; TRANSPLANTATION CHIMERA;

EID: 79958782091     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.014555     Document Type: Article

References (41)

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121-1135.
2. Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol. 1960;70:68-78.
3. Jolly SR, Kane WJ, Hook BG, Abrams GD, Kunkel SL, Lucchesi BR. Reduction of myocardial infarct size by neutrophil depletion: effect of duration of occlusion. Am Heart J. 1986;112:682-690. (Pubitemid 16025029)
4. Entman ML, Michael L, Rossen RD, Dreyer WJ, Anderson DC, Taylor AA, Smith CW. Inflammation in the course of early myocardial ischemia. Faseb J. 1991;5:2529-2537. (Pubitemid 21905802)
5. Sisley AC, Desai T, Harig JM, Gewertz BL. Neutrophil depletion attenuates human intestinal reperfusion injury. J Surg Res. 1994;57: 192-196. (Pubitemid 24243259)
6. Nachman RL, Weksler B. The platelet as an inflammatory cell. Ann N Y Acad Sci. 1972;201:131-137.
7. Weyrich AS, Zimmerman GA. Platelets: Signaling cells in the immune continuum. Trends Immunol. 2004;25:489-495. (Pubitemid 39490256)
8. Xu Y, Huo Y, Toufektsian MC, Ramos SI, Ma Y, Tejani AD, French BA, Yang Z. Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol Heart Circ Physiol. 2006;290: H692-H699.
9. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest. 2006;116:3211-3219. (Pubitemid 44878635)
10. Weissmuller T, Campbell EL, Rosenberger P, Scully M, Beck PL, Furuta GT, Colgan SP. PMNs facilitate translocation of platelets across human and mouse epithelium and together alter fluid homeostasis via epithelial cell- expressed ecto-NTPDases. J Clin Invest. 2008;118:3682-3692.
11. Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet- neutrophilinteractions: linking hemostasis and inflammation. Blood Rev. 2007;21: 99-111.
12. Altmann C, Meyer Zu, Heringdorf D, Boyukbas D, Haude M, Jakobs KH, Michel MC. Sphingosylphosphorylcholine, a naturally occurring lipid mediator, inhibits human platelet function. Br J Pharmacol. 2003;138: 435-444. (Pubitemid 36269484)
13. Bennett JS, Zigmond S, Vilaire G, Cunningham ME, Bednar B. The platelet cytoskeleton regulates the affinity of the integrin alpha(iib)beta(3) for fibrinogen. J Biol Chem. 1999;274:25301-25307.
14. Bear JE, Gertler FB. ENA/VASP: towards resolving a pointed controversy at the barbed end. J Cell Sci. 2009;122:1947-1953.
15. Ferron F, Rebowski G, Lee SH, Dominguez R. Structural basis for the recruitment of profilin-actin complexes during filament elongation by ENA/VASP. Embo J. 2007;26:4597-4606. (Pubitemid 350036631)
16. Bachmann C, Fischer L, Walter U, Reinhard M. The EVH2 domain of the vasodilator-stimulated phosphoprotein mediates tetramerization, F-actin binding, and actin bundle formation. J Biol Chem. 1999;274: 23549-23557.
17. Holt MR, Critchley DR, Brindle NP. The focal adhesion phosphoprotein, VASP. Int J Biochem Cell Biol. 1998;30:307-311. (Pubitemid 28234224)
18. Walter U, Gambaryan S. cGMP and cGMP-dependent protein kinase in platelets and blood cells. Handb Exp Pharmacol. 2009:533-548.
19. Anderson SI, Behrendt B, Machesky LM, Insall RH, Nash GB. Linked regulation of motility and integrin function in activated migrating neutrophils revealed by interference in remodelling of the cytoskeleton. Cell Motil Cytoskeleton. 2003;54:135-146. (Pubitemid 36158159)
20. Oberprieler NG, Roberts W, Graham AM, Homer-Vanniasinkam S, Naseem KM. Inhibition of ADP-induced platelet adhesion to immobilised fibrinogen by nitric oxide: evidence for cGMP-independent mechanisms. Biochem Pharmacol. 2007;73:1593-1601. (Pubitemid 46527540)
21. Morel O, Faure A, Ohlmann P, Jesel L, Desprez D, Grunebaum L, Bareiss P. Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis. Thromb Haemost. 2007; 98:896-899. (Pubitemid 47555085)
22. Geiger J, Brich J, Honig-Liedl P, Eigenthaler M, Schanzenbacher P, Herbert JM, Walter U. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol. 1999;19:2007-2011. (Pubitemid 29379936)
23. Henes J, Schmit MA, Morote-Garcia JC, Mirakaj V, Kohler D, Glover L, Eldh T, Walter U, Karhausen J, Colgan SP, Rosenberger P. Inflammationassociated repression of vasodilator-stimulated phosphoprotein (VASP) reduces alveolar-capillary barrier function during acute lung injury. Faseb J. 2009;23:4244-4255.
24. Eckle T, Grenz A, Kohler D, Redel A, Falk M, Rolauffs B, Osswald H, Kehl F, Eltzschig HK. Systematic evaluation of a novel model for cardiac ischemic preconditioning in mice. Am J Physiol Heart Circ Physiol. 2006;291:H2533-H2540.
25. Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, Corday E, Ganz W. Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J. 1981;101:593-600. (Pubitemid 11120523)
26. Rosenberger P, Schwab JM, Mirakaj V, Masekowsky E, Mager A, Morote-Garcia JC, Unertl K, Eltzschig HK. Hypoxia-inducible factor- dependent induction of netrin-1 dampens inflammation caused by hypoxia. Nat Immunol. 2009;10:195-202.
27. Straub A, Wendel HP, Dietz K, Schiebold D, Peter K, Schoenwaelder SM, Ziemer G. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation. Thromb Haemost. 2008;99: 609-615. (Pubitemid 351549299)
28. Horstrup K, Jablonka B, Honig-Liedl P, Just M, Kochsiek K, Walter U. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur J Biochem. 1994;225:21-27. (Pubitemid 24306224)
29. Jensen BO, Selheim F, Doskeland SO, Gear AR, Holmsen H. Protein kinase a mediates inhibition of the thrombin-induced platelet shape change by nitric oxide. Blood. 2004;104:2775-2782. (Pubitemid 39434961)
30. Weber C, Springer TA. Neutrophil accumulation on activated, surfaceadherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaiibbeta3 and stimulated by platelet-activating factor. J Clin Invest. 1997;100:2085-2093. (Pubitemid 27459364)
31. Chen H, Levine YC, Golan DE, Michel T, Lin AJ. Atrial natriuretic peptide-initiated cGMP pathways regulate vasodilator-stimulated phosphoprotein phosphorylation and angiogenesis in vascular endothelium. J Biol Chem. 2008;283:4439-4447.
32. Comerford KM, Lawrence DW, Synnestvedt K, Levi BP, Colgan SP. Role of vasodilator-stimulated phosphoprotein in PKA-induced changes in endothelial junctional permeability. Faseb J. 2002;16:583-585.
33. Kim D, Aizawa T, Wei H, Pi X, Rybalkin SD, Berk BC, Yan C. Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling. J Mol Cell Cardiol. 2005;38:175-184. (Pubitemid 40038664)
34. Scotland RS, Cohen M, Foster P, Lovell M, Mathur A, Ahluwalia A, Hobbs AJ. C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. Proc Natl Acad Sci USA. 2005;102:14452-14457. (Pubitemid 41429718)
35. Massberg S, Gruner S, Konrad I, Garcia Arguinzonis MI, Eigenthaler M, Hemler K, Kersting J, Schulz C, Muller I, Besta F, Nieswandt B, Heinzmann U, Walter U, Gawaz M. Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)-deficient mice. Blood. 2004;103:136-142. (Pubitemid 38029929)
36. Kawamura T, Nara N, Kadosaki M, Inada K, Endo S. Prostaglandin E1 reduces myocardial reperfusion injury by inhibiting proinflammatory cytokines production during cardiac surgery. Crit Care Med. 2000;28: 2201-2208. (Pubitemid 30604416)
37. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, Seguchi O, Myoishi M, Minamino T, Ohara T, Nagai Y, Nanto S, Watanabe K, Fukuzawa S, Hirayama A, Nakamura N, Kimura K, Fujii K, Ishihara M, Saito Y, Tomoike H, Kitamura S. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007; 370:1483-1493. (Pubitemid 47625560)
38. Kupatt C, Habazettl H, Hanusch P, Wichels R, Hahnel D, Becker BF, Boekstegers P. C7E3Fab reduces postischemic leukocyte-thrombo- cyte interaction mediated by fibrinogen: implications for myocardial reperfusion injury. Arterioscler Thromb Vasc Biol. 2000;20:2226-2232.
39. Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest. 2009;119: 3450-3461.
40. Kohler D, Eckle T, Faigle M, Grenz A, Mittelbronn M, Laucher S, Hart ML, Robson SC, Muller CE, Eltzschig HK. CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation. 2007;116: 1784-1794. (Pubitemid 350287103)
41. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189. (Pubitemid 40397259)